NCT05098184View on ClinicalTrials.gov

Study on TIL for the Treatment of Advanced Melanoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 26, 2021

Primary Completion Date

September 25, 2026

Study Completion Date

September 25, 2026

Conditions
Advanced MelanomaTumor Infiltrating LymphocyteTreatment Side EffectsEffects of Immunotherapy
Interventions
BIOLOGICAL

Tumor Infiltrating Lymphocyte

Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Tenth People's Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai 10th People's Hospital

OTHER

lead

Shanghai Juncell Therapeutics

INDUSTRY